PureTech Health Notes U.S. Patent Issuance Broadly Covering Methods of Assessing Mental and Physical Condition from Human Spe...
September 20 2017 - 2:00AM
Business Wire
PureTech Health plc (“PureTech Health” or the “Company”, LSE:
PRTC), an advanced, clinical-stage biopharmaceutical company, is
pleased to note that the United States Patent and Trademark Office
(USPTO) has issued U.S. Patent No. 9,763,617 for its Sonde vocal
biomarkers program. The patent broadly covers methods of assessing
a mental or physical condition of a subject, using phonetic
structures, or phones, extracted from speech audio waveforms. The
issued patent is exclusively licensed under an agreement with the
Massachusetts Institute of Technology (MIT) and provides coverage
through at least 2032.
“This newly issued patent represents, to the best of our
knowledge, the only coverage for novel vocal biomarkers that have
been demonstrated to enhance vocal analysis performance for
assessment of a broad range of diseases,” said Jim Harper, Ph.D.,
PureTech Health Vocal Biomarker Program Lead. “Issuance of this
patent strengthens our leading intellectual property portfolio in
the emerging field of acoustic voice analysis for health, and it
provides validation of our novel vocal biomarkers technology for
the assessment of mental and physical conditions.”
The patented technology, created by a team at MIT Lincoln
Laboratory led by Thomas Quatieri, Ph.D., enables analysis of
subtle - yet quantifiable - changes in the voice to improve
automated measures of important aspects of an individual’s health.
Pilot studies using the exclusively licensed technology have also
demonstrated the potential to detect and objectively measure
symptoms in a range of important conditions including depression,
mild traumatic brain injury (mTBI), concussion, cognitive
impairment and Parkinson’s Disease. The vocal biomarkers program
(Sonde) has been integrating and extending this technology for
analysis of an individual’s voice on commonly-owned devices.
Testing of the Sonde technology in over a thousand subjects has
demonstrated the potential to effectively screen and monitor for
disease using only a few seconds of voice. The Sonde technology is
being developed to enable disease-associated features of speech to
be measured without capturing the contents of speech, therefore
protecting privacy.
About PureTech HealthPureTech Health (PureTech
Health plc, PRTC.L) is an advanced, clinical-stage
biopharmaceutical company developing novel medicines targeting
serious diseases that result from dysfunctions in the nervous,
immune, and gastrointestinal systems (brain-immune-gut or the “BIG”
axis), which together represent the adaptive human systems.
PureTech Health is at the forefront of understanding and addressing
the biological processes and crosstalk associated with the BIG
axis. By harnessing this emerging field of human biology, the
Company is pioneering new categories of medicine with the potential
to have great impact on people with serious diseases. PureTech
Health is advancing a rich pipeline of innovative therapies that
includes two pivotal or registration studies expected to read out
in 2017, multiple human proof-of-concept studies and a number of
early clinical and pre-clinical programs. PureTech’s rich research
and development pipeline has been advanced in collaboration with
some of the world’s leading scientific experts, who along with
PureTech's team of biopharma pioneers, entrepreneurs and seasoned
Board, identify, invent, and clinically de-risk new medicines. With
this experienced team pursuing cutting edge science, PureTech
Health is building the biopharma company of the future focused on
improving and extending the lives of people with serious disease.
For more information, visit www.puretechhealth.com or connect with
us on Twitter @puretechh.
Forward Looking StatementThis press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from current
expectations, including, but not limited to, those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170919006729/en/
PureTech HealthAllison Mead Talbot,
+1-617-651-3156amt@puretechhealth.com
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2023 to Apr 2024